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Abstract
Introduction: The immune modulatory role of estrogens in inflammation is complex. Both pro- and anti-inflammatory 
effects of estrogens have been described. Estrogens bind both estrogen receptor (ER)α and β. The contribution of ERα 
and ERβ to ER-mediated immune modulation was studied in delayed type hypersensitivity (DTH) and in experimental 
arthritis
Methods: ER-mediated suppression of rat adjuvant arthritis (AA) was studied using ethinyl-estradiol (EE) and a 
selective ERβ agonist (ERB-79). Arthritis was followed for 2 weeks. Next, effects of ER agonists (ethinyl-estradiol, an ERα 
selective agonist (ERA-63) and a selective ERβ agonist (ERB-79) on the development of a tetanus toxoid (TT)-specific 
delayed type hypersensitivity response in wild type (WT) and in ERα - or ERβ-deficient mice were investigated. Finally, 
EE and ERA-63 were tested for their immune modulating potential in established collagen induced arthritis in DBA/1J 
mice. Arthritis was followed for three weeks. Joint pathology was examined by histology and radiology. Local synovial 
cytokine production was analyzed using Luminex technology. Sera were assessed for COMP as a biomarker of cartilage 
destruction.
Results: EE was found to suppress clinical signs and symptoms in rat AA. The selective ERβ agonist ERB-79 had no 
effect on arthritis symptoms in this model. In the TT-specific DTH model, EE and the selective ERα agonist ERA-63 
suppressed the TT-specific swelling response in WT and ERβKO mice but not in ERαKO mice. As seen in the AA model, 
the selective ERβ agonist ERB-79 did not suppress inflammation. Treatment with EE or ERA-63 suppressed clinical signs 
in collagen induced arthritis (CIA) in WT mice. This was associated with reduced inflammatory infiltrates and decreased 
levels of proinflammatory cytokines in CIA joints.
Conclusions: ERα, but not ERβ, is key in ER-mediated suppression of experimental arthritis. It remains to be 
investigated how these findings translate to human autoimmune disease.
Introduction
I t  i s  w e l l  k n o w n  t h a t  m a n y  a u t o i m m u n e  d i s e a s e s  a r e
more prevalent in women than in men [1]. More specifi-
cally, rheumatoid arthritis (RA) is often diagnosed in the
childbearing years when both onset and exacerbations
are associated with the post-partum period, and preg-
nancy is associated with milder disease symptoms [2,3].
In addition, RA incidence peaks in the postmenopausal
state associated with a drop in endogenous estrogen lev-
els [4,5]. These early findings suggested an important role
for female sex hormones in chronic inflammatory dis-
ease.
Animal models have been widely used to study the role
of female sex hormones in inflammation. Ovariectomy-
induced loss of endogenous estrogen production in
female DBA/1 mice increased arthritic signs in collagen-
induced arthritis (CIA) [6]. Female mice, similar to the
human situation, show pregnancy-associated protection
of joint disease with post-partum flares of arthritis [7].
The post-partum flare seen in CIA was suppressed by
exogenous administration of ethinyl-estradiol (EE) but
* Correspondence: john.dulos@spcorp.com
Schering-Plough Research Institute, PO box 20, 5340 BH Oss, The Netherlands
Full list of author information is available at the end of the articleDulos et al. Arthritis Research & Therapy 2010, 12:R101
http://arthritis-research.com/content/12/3/R101
Page 2 of 12
not with progesterone and hydrocortisone [7]. Levels of
EE that were suppressive were comparable with estrogen
levels seen at pregnancy. Similar results have now been
reported for estrogens in experimental autoimmune
models such as experimental autoimmune encephalomy-
elitis (EAE) and experimental AA [8-10]. In contrast,
estrogen was found to accelerate autoimmune phenom-
ena in experimental systemic lupus erythromatosus (SLE)
[11].
Estrogens mediate their immune modulatory effects via
classical estrogen receptors (ERs) [12]. Cloning of ERα
was first reported in 1986 [13]. Ten years later a second
receptor was identified in mice, rats and humans, and was
named ERβ [14-16]. ER expression has been described in
various cell types involved in inflammatory processes
including T cells, B cells, dendritic cells, monocytes and
macrophages [17-19]. Differential expression of the ER
subtypes in different cell types and in different microen-
vironments may thus impact estrogen-mediated effects
[20]. Interestingly, relatively high ERβ expression levels
were observed in synovial tissue of RA patients; ERβ
dominant expression was reported in synovial fibroblasts,
inflammatory cells and in the synovial lining layer [21,22].
The data suggest an inflammation-dependent upregula-
tion of ERβ relative to ERα in RA.
In experimental arthritis, most studies report an
immune suppressive effect of E2 or EE, which bind both
ERs in an agonistic mode [23,24]. This finding is in line
with an earlier onset of arthritis in mice when treated
with the ERα/β antagonist ICI 182780 [10]. Harris and
colleagues have reported ERβ-mediated suppression of
inflammation in rat adjuvant arthritis and in the HLA-
B27 transgenic rat model of inflammatory bowel disease
using the ERβ selective agonist ERB-041 [25].
Here, we chose to investigate the relative contribution
of ERα or ERβ to ER-mediated immune-suppression in
vivo. To this end, both selective ERα and ERβ agonistic
compounds and ERα-and ERβ-deficient mice were used.
First, ER-mediated immune modulation was evaluated in
lewis rat adjuvant arthritis. Second, we investigated ER-
mediated suppression of the tetanus-toxoid (TT)-specific
delayed type hypersensitivity (DTH) in wild type, ERα-
deficient and ERβ-deficient mice. Finally, EE and a selec-
tive ERα agonist compound were evaluated in an estab-
lished CIA. Our data show an important role for ERα but
not ERβ in suppression of inflammatory processes in
experimental arthritis.
Materials and methods
Mice and rats
All the experiments were approved by the Animal Wel-
fare Committee of Schering-Plough, Oss, The Nether-
lands.
Pharmacokinetics of EE, ERA-63 and ERB-79
Due to the poor oral bioavailability of estrogens, treat-
ment in most of the animal models described so far
involved the use of estrogen injections or implantation of
estrogens such as E2. We used the synthetic estrogen EE,
synthesized in house, at dosages that have been described
to be orally effective in the treatment of EAE and CIA
[23,26] The pharmacologic properties for the ERα agonist
ERA-63 (Org 37663) have been described previously
showing efficacy in inflammatory models at 1.5 mg/kg
[27]. For both EE and ERA-63, the increase in uterus
weight can be considered a pharmacodynamic marker of
estrogenic activity in vivo [28]. Pharmacologic character-
ization of the selective ERβ agonist ERB-79 in rats has
recently been reported [29]. ERB-79 is an ERβ agonist
displaying a more than 484-fold selectivity over ERα
based on in vitro ERα transactivation and ERβ transacti-
vation assays with EC50 values of 7.9 × 10-8 M (potency of
0.03% relative to E2) versus 4.48 × 10-10 M (potency of
14.52% relative to E2), respectively. The compound has
no ERα or ERβ antagonistic properties.
In order to arrive at a dose of ERB-79 engaging ERβ but
not ERα in mice, an in vivo titration for ERα activity was
performed. T o that end, female DBA/1J mice were ova-
riectomized and treated, daily, by subcutaneous injection,
for 21 days with EE (0.025 mg/kg) or ERB-79 at a dose of
1 mg/kg, 3 mg/kg or 10 mg/kg. Next, uteri were dissected
free, weighted and thereafter processed for histological
examination. ERB-79 increased the more ERα sensitive
marker of epithelial cell height at 3 mg/kg or more ERB-
79 (Table a1a). However, at that dose no ERα- mediated
effect was seen on uterus weight. In the present study we
thus chose a dose of 3 mg/kg subcutaneous yielding
plasma level concentrations (around 1 × 10-8 M) adequate
for engaging ERβ but unlikely to engage ERα.
Lewis rat adjuvant-induced arthritis
The study investigating effects of EE and ERB-79 on
modulation of rat AA were carried out according to a
standardized protocol. In brief, male Lewis rats were
immunized by subcutaneous injection in the tail base
with 0.1 ml (1 mg) Mycobacterium tuberculosis in com-
plete Freund's Adjuvant (Difco Lab. Detroit, IL, USA).
Rats (n = 8 per treatment group) were left untreated or
were treated subcutaneously once daily with vehicle (gel-
atin 0.5%-mannitol 5% in water), dexamethasone (1 mg/
kg), EE (2.5 mg/kg) or the selective ERβ agonist ERB-79 (3
mg/kg). Treatment started on day 10 when the first signs
of disease activity were observed. Rats were evaluated
daily (once during weekends) for arthritis severity using a
macroscopic scoring system of 0 to 4 (0 = no signs of
arthritis, 0.5 = partial limping/unloading of paw, 1 = red-
ness of the paw and inability to fully stretch ankle joint, 2Dulos et al. Arthritis Research & Therapy 2010, 12:R101
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= moderate swelling and redness of paw, 3 = severe red-
ness and swelling of entire paw including digits, 4 = max-
imally inflamed paw, multiple joints involved). For each
rat, the cum ulative score was calculated by adding the
scores obtained from day 0 to day 24 and presented as the
mean ± standard error of the mean (n = 8 rats per group).
Statistical analysis was performed using analysis of vari-
ance (ANOVA) followed by post hoc Least Significant
Difference (LSD) test (*** P ≤ 0.001).
Tetanus-toxoid-induced footpad swelling
In order to exclude a major source of endogenous estro-
gen production, female C57bl/6 mice of 8 to 10 weeks of
age were bilaterally ovariectomized under anesthesia.
During a recovery period of about one week vaginal
smears were taken daily to record the phase of the estrous
cycle and only animals devoid of cyclic activity were
included in the experiment. In all DTH experiments, ani-
mals were immunized at day 0 with 50 μl TT mixed in
dimethyl dioctadecyl ammonium bromide (37.5 Lf TT/
ml of dimethyl dioctadecyl ammonium bromide) intrad-
ermally in the back, just below the neck, at two different
sites (2 × 50 ul). At day 7, animals were challenged intrad-
ermally with 50 μl TT mixed in Al(OH)3 (50 Lf TT in 1
mg/ml Al(OH)3) in the left footpad (ventral side). The
right control footpad received vehicle only. Twenty-four
hours later the left and right hind footpad thickness was
measured with a micrometer designed in-house and the
Δmm of antigen-specific footpad swelling was calculated
according to the following formula: ((swelling left (mm)
minus swelling right (mm)). At autopsy (48 hours later)
the uterus was removed and weighted.
WT C57bl/6 (n = 8 per group) mice were ovariecto-
mized and treated once daily orally with the selective ERα
agonist ERA-63 (6 mg/kg), EE (0.025, 0.25 and 2.5 mg/kg)
or vehicle (0.5% gelatin- 5% mannitol in water) only from
day -1 to day 9. The selective ERβ agonist ERB-79 (3 mg/
kg) was administered subcutaneously and compared with
vehicle (subcutaneous).
Further DTH validation experiments were performed
with ERα - and ERβ-deficient mice. ERαKO mice were
obtained from Iafrati [30]. The ERβKO mice were gener-
ated in-house and fully characterized [31]. ERαKO,
ERβKO and WT were ovariectomized and treated once
daily orally with the selective ERα agonist ERA-63 (6 mg/
kg) or vehicle (0.5% gelatin and 5% mannitol in water)
from day -1 to day 9. The DTH response was assessed as
before.
Therapeutic murine collagen-induced arthritis
The murine CIA model was performed as described [32].
In brief, male DBA1/J mice were obtained from Bomholt-
gard (Ry, Denmark). Animals were housed and main-
tained at 23°C with water and food ad libitum. Mice were
immunized at the base of the tail at day 0 (at the age of
eight weeks) with 100 μg bovine type II collagen in com-
plete Freund's adjuvant enriched with 2 mg/ml M. tuber-
culosis (H37Ra). Three weeks after immunization (at day
21) the animals were boosted with an intra-peritoneal
injection of 100 μg collagen type II, dissolved in saline.
After disease onset, animals with an arthritis score rang-
ing from 0.25 and 1.25 were divided into separate groups
of 12 mice so that the mean arthritis score of all groups
was comparable at the start of treatment (day 0). Mice
w e r e  c o n s i d e r e d  t o  h a v e  a r t h r i t i s  w h e n  s i g n i f i c a n t
changes in redness and/or swelling were noted in the dig-
its or in other parts of the paws. Arthritic animals were
treated orally once daily for a period of 21 days with
0.025, 0.25 or 2.5 mg/kg EE in vehicle (0.5% gelatin and
5% mannitol in water), 0.75, 1.5 or 3 mg/kg Erα-agonist
Table 1: Effect of EE and ERB-79 on uterus weight and luminal epithelial height
Dose Uterus weight
(mg: mean ± SD)
Uterus Luminal
epithelial height
(μM: mean ± SD)
Vehicle sc - 14.6 ± 9.5 11.7 ± 1.1
EE sc 0.025 107.6 ± 20.2* 28.5 ± 1.8*
ERB-79 sc 1 9.7 ± 2.5 11.8 ± 1.1
ERB-79 sc 3 14.2 ± 2.7 13.7 ± 1.5*
ERB-79 sc 10 18.2 ± 4.2 14.1 ± 0.8*
After ovariectomy of female DBA/1J mice, mice were treated daily subcutaneaously, for 21 days with vehicle (0.5% gelatin and 5% mannitol 
in water), the estrogen receptor (ER)α/β agonist ethinyl estradiol (EE; 0.025 mg/kg) or the ERβ agonist ERB-79 at 1 mg/kg, 3 mg/kg and 10 mg/
kg (n = 8 mice per treatment group). Uterus was dissected free, weighted and thereafter fixed in 4% formaldehyde. Uterus was embedded in 
paraffin and sections were stained with hematoxylin and eosin. Microscopical images are captured and measured at 125-fold magnification 
using an automated image analysis system (UltraSpark, Iduna Elektronics BV, Veghel, The Netherlands). Of each mouse at least two cross 
sections and two fields per section are measured. The mean epithelial height is measured over a stretch of luminal epithelium that is clearly 
transversely cut. All measurements per mouse are used to calculate one mean Luminal Epithelial Height (LEH) value for that animal. (* P ≤ 
0.05: Statistical analysis was performed using one-way analysis of variance). sc, subcutaneous; SD, standard deviation.Dulos et al. Arthritis Research & Therapy 2010, 12:R101
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ERA-63 in vehicle, or vehicle alone. As a positive control
for suppression of arthritis, animals were treated orally
with 1.5 or 3 mg/kg prednisolone in vehicle. All experi-
mental treatments were conducted in a blinded fashion.
The clinical severity of arthritis (arthritis score) was
graded (a scale of 0 to 2 for each paw). Mice were scored
on alternative days, resulting in mean scores with a maxi-
mum of 2 for each paw, and an overall maximum of 8 per
animal. To assess the effects of treatment, the area under
the curve (AUC) of mean arthritis score of each animal
with baseline correction (subtracting baseline AUC of
arthritis score on day 0) was used. At the end of the
experiment (21 days of treatment) knee synovial biopsies,
hind paws and serum samples were obtained. Hind paws
were evaluated using X-ray analysis [33] to assess bone
destruction. X-ray photographs were examined with a
Faxitron X-ray MX-20 (0.02 mm resolution) and bone
destruction was scored on a scale from 0 to 5 ranging
from no damage to complete destruction [34]. For histo-
pathological analysis (infiltration and cartilage destruc-
tion) knee joints were fixed in 4% formaldehyde,
decalcified in 5% formic acid and processed and evalu-
ated as described [33]. Hematoxylin and eosin-stained
sections (7 μM) were used to study joint inflammation.
The severity of inflammation in joints was scored on a
scale of 0 to 3 (0 = no cells, 1 = mild cellularity, 2 = mod-
erate cellularity and 3 = maximal cellularity). To study
proteoglycan depletion from the cartilage matrix, sec-
tions were stained with safranin O. Depletion of proteo-
glycan was scored on an arbitrary scale of 0 to 3 ranging
from normal fully stained cartilage to destained cartilage.
To analyze cytokine levels with Luminex (Bio-rad, Her-
cules, CA, USA) technology, knee synovial biopsies were
isolated as described [33], frozen in liquid nitrogen and
stored at -70°C until use (see section cytokine and
chemokine protein levels by Luminex).
Cytokine and chemokine protein detection in CIA synovial 
tissue
To investigate the presence of cytokines/chemokines pro-
duced locally, knee synovial biopsy samples were isolated
from vehicle and estrogen-treated mice. Knee synovial
biopsy samples were pooled (n = 6 per treatment group),
weighed and cut into small pieces with a scissor. Lysis
solution was added containing 100 mmol/L potassium
phosphate (PH 7.8), 0.2% Triton X-100, 1 mmol/L dithio-
threitol and 1 mM protease inhibitor (prefabloc from
Boehringer, Mannheim, Germany). The volume of lysis
buffer was adjusted to 250 mg of tissue per ml. After the
lysis buffer was added, the samples were placed on ice for
15 minutes and thereafter centrifuged for 30 minutes at
500 g. The amount of protein in the supernatant was
determined using the BCA assay and the samples were
aliquoted and stored at -70°C until use.
For simultaneous detection of 18 cytokines in one sam-
ple we used the Bio-Plex/Luminex mouse cytokine 18-
plex panel kit, which includes antibody-conjugated
beads, detection antibody and standards for detection of
IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12p40,
IL-12p70, IL-17, Granulocyte-Colony Stimulating Factor
(G-CSF), Granylocyte Macrophage Colony stimulating
factor (GM-CSF), interferon (IFN)γ, the murine IL-8
homoloque KC, Macrophage Inhibitory Protein-1 (MIP-
1α), Chemokine (C-C motif) ligand 5 also known as
CCL5 or RANTES and TNFα using a 96-well round-bot-
tomed micro titer plate as described by the manufacturer
(Biorad, Hercules, CA, USA). Pooled supernatants from
knee biopsy samples were diluted once in assay dilutent.
Samples were incubated for 30 minutes on ice with anti-
body-conjugated beads, washed and thereafter incubated
for 30 minutes with biotinylated antibody. After washing,
streptavidin-PE was added and incubated for 10 minutes.
The Bioplex-protein assay reader from Luminex was
used. The amount (pg) of cytokine/chemokine per mg
protein (pg/mg) was calculated.
Statistical analysis
All statistics were performed using SAS. TT-DTH data
were analyzed with ANOVA on factors treatment and
strain (wild type and knockout) and interaction between
treatment and strain. Comparisons with vehicle treat-
ment was performed. Cartilage Oligomeric Matrix Pro-
tein (COMP) and cytokine/chemokine levels were
analyzed with the Mann-Whitney U test (two-tailed)
whereby treatment is compared with vehicle. Arthritis
scores were analyzed with ANOVA. Estrogen- or predni-
solone-treated groups were compared with vehicle (* P <
0.05, ** P < 0.01, *** P < 0.001) using the LSD post hoc
comparison test.
Results
EE but not ERB-79 suppresses lewis rat AA
Previously, ERβ-mediated suppression of inflammation in
Lewis  r a t  AA  was  r epo rt ed  [ 2 5 ] .  T h is  p r o m p t ed  us  t o
study the effects of EE and our selective ERB-79 in rat
AA. The ERB-79 dose of 3 mg/kg was chosen on the basis
of prior studies showing ERβ but not ERα engagement
[29]. EE at a dose of 0.25 mg/kg when administered sub-
cutaneously significantly suppressed the arthritis score in
this model as assessed by the AUC (Figure 1). The inhibi-
tion of inflammation by EE was partial. Dexamethasone,
the positive treatment control, was able to suppress
inflammation completely. Interestingly, the selective
ERB-79 when dosed at 3 mg/kg subcutaneously did not
suppress clinical signs of arthritis in this model. In addi-
tion, arthritis incidence and onset in ERB-79-treated ani-
mals was not affected (data not shown). The data implyDulos et al. Arthritis Research & Therapy 2010, 12:R101
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that estrogen-mediated suppression in rat AA is ERα
mediated.
The estrogen-mediated suppression of the TT-DTH in wild 
type mice is dependent on ERα
Next, we assessed the relative contribution of ERα and
ERβ to ER-mediated immune modulation in the mouse.
To this end, the TT-DTH model was used in ovariecto-
mized mice. Mice were treated with the ERα-agonist
ERA-63, the ERβ-agonist ERB-79 or the non-selective
estrogen EE whereby the ERα-sensitive uterus weight was
used as a pharmacodynamic readout control. For ERB-79,
the more sensitive marker of epithelial cell height was
used to establish a dose range securing ERβ but not ERα
activity (3 mg/kg; Table 1).
As expected, the glucocorticoid dexamethasone and
ERB-79, at a pharmacologic defined concentration,
engaged ERβ but not ERα, showed no effect on uterus
weights (Table 2). The glucocorticoid dexamethasone,
which is used as a positive anti-inflammatory control,
strongly inhibited the TT-specific footpad swelling (Table
2). Also, a significant suppressive effect of oral treatment
with EE (at both 0.25 mg/kg to 2.5 mg/kg) on TT-specific
footpad swelling was observed (Table 2). Interestingly,
ERA-63 dose-dependently decreased the TT-specific
response whereas treatment with the ERβ-agonist ERB-
79 had no effect on TT-specific swelling.
To study whether estrogens modulate the antigen-spe-
cific humoral immune response, sera from estrogen-
treated mice were assayed for TT-specific antibodies
using an ELISA. TT-specific IgG1 titers were clearly sup-
pressed following treatment with dexamethasone and
were minimally affected following treatment with either
EE or ERα-agonist ERA-63 (data not shown). Our data
show that the TT-specific cellular response (TT-specific
swelling) is more sensitive to estrogen-mediated suppres-
sion than TT-specific IgG1 production.
ERA-63 inhibits the tetanus toxoid (TT)-specific DTH 
response in WT and ERβ-/- mice but not in ERα-/- mice
To further substantiate our findings on ERα-mediated
immune suppression, we evaluated ERA-63 on suppres-
sion of the TT-specific DTH in wild type, ERα-/- and
ERβ-/- mice. Again, we used the uterus weights as a PD
marker for the classic estrogenic effect. ERA-63 when
t e s t e d  a t  o n e ,  r e l a t i v e l y  h i g h ,  d a i l y ,  d o s e  o f  6  m g / k g ,
increased the uterus weights in wild type C57bl/6 mice
and in ERβ-/- but not in ERα-/- mice, thereby providing
further evidence that the increase in uterus weight is
indeed mediated via ERα (Figure 2a). Interestingly, after
treatment with ERA-63, a more profound increase in
uterus weight was observed in ERβ-/- mice when com-
pared with wild type mice. This may be explained by
either an increase in ERα receptor expression in ERβ-/-
mice [35] or a lack of ERβ -mediated inhibition of ERα
signaling [36].
In wild type, ERα-/- and ERβ-/- mice, a similar level of
TT-specific swelling was observed in vehicle-treated
mice, which allowed for further compound profiling in
this model (Figure 2b). Importantly, treatment with the
ERα-agonist ERA-63 decreased the DTH response in
both wild type and ERβ-/- but not in ERα-/- mice (Figure
2b). The results confirm that suppression of inflamma-
tion in vivo is mediated via ERα but not ERβ.
The estrogen-mediated suppression of inflammation and 
joint destruction in murine CIA is dependent on ERα
To further confirm that the anti-arthritic properties of
estrogens are mediated via ERα, arthritic male DBA/1
mice were orally treated with the ER non-selective estro-
gen EE, when administered therapeutically in similar
doses as used in the TT-DTH. A dose-dependent reduc-
tion of disease severity was observed (Figure 3a). When
examined by AUC analysis covering the entire treatment
period, a significant reduction of the AUC arthritis score
was seen (Figure 3b). To determine whether the estrogen-
induced immune modulation in this model was indeed
mediated through ERα, we used the ERα-agonist ERA-63.
Therapeutic administration of the selective agonist ERA-
63 decreased the clinical signs of arthritis dose-depend-
ently (Figure 3c). In addition, the AUC analysis over the
20-day treatment period revealed a significant dose-
dependent reduction in the ERA-63-treated mice when
compared with vehicle control (Figure 3d).
Histopathological and x-ray analysis of the arthritic
joints indicated severe cartilage and bone destruction in
the vehicle-treated animals (Figures 4a and 4b). In con-
trast, EE treatment reduced the amount of inflammatory
cells (infiltrate) and measures of cartilage- and bone-
Figure 1 No role for ERβ in modulation of rat AA. Male lewis rats 
were injected with complete freund's adjuvant containing mycobac-
terium tuberculosis. Daily treatment (subcutaneous) with dexametha-
sone (1 mg/kg), ethinyl estradiol (EE at 2.5 mg/kg), ERB-79 (3 mg/kg) or 
vehicle (0.5% gelatin- 5% mannitol) started when the first signs of ar-
thritis were observed (day 10). Animals (n = 8 per group) were scored 
daily for arthritis. Statistical analysis was performed using analysis of 
variance followed by post hoc Least Significant Difference (LSD)test (*** 
P ≤ 0.001). AUC, area under the curve. ER, estrogen receptor.
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destruction significantly. In CIA, serum COMP levels are
increased due to enhanced cartilage destruction. Thera-
peutic treatment with EE decreased the serum COMP
(biomarker of cartilage destruction) levels in CIA, which
is in line with the protective effect of EE on cartilage
destruction as measured with histopathology (Figure 4a).
As expected, the ERA-63 suppressed inflammation
(AUC) scores in CIA were accompanied by reduced
inflammatory infiltrates and cartilage destruction scores
at the level of the joint (Figure 4b). The reduced cartilage
destruction was associated with a dose-dependent
decrease of serum COMP levels. Also, x-ray analysis
revealed reduced bone destruction (Figure 4b).
ERα-mediated immune-suppression is associated with 
locally decreased IL-1β, IL-6, IL-12p40, KC and RANTES 
protein levels
It has been reported that CIA is IL-1β and TNFα depen-
dent. Both cytokines have a prominent role in mecha-
nisms underlying joint destruction [32]. Joint synovial
cytokines and chemokines were thus measured to evalu-
ate whether the mechanism of ERα-mediated immune-
suppression is associated with changed levels of cytok-
ines such as IL-1β. Of 18 different cytokines and chemok-
ines evaluated, EE significantly decreased the amount of
IL-1β, IL-6, IL-12p40, KC and RANTES (Table 3). IL-1α,
IL-2, IL-3, IL-4, IL-5, IL-10, IL-12p70, IL-17, G-CSF, GM-
CSF, IFNγ, MIP-1α and TNFα were not detected in the
synovium at this stage of the disease process. Impor-
tantly, treatment with the ERα-agonist ERA-63 at higher
dosages similarly decreased the level of IL-1β, IL-6, IL-
12p40, KC and RANTES, which is in full agreement with
the effect of EE treatment (Table 3).
In summary, our results present a strong case for ERα-
mediated suppression of the inflammatory response in
rat AA and in established mouse CIA where it is associ-
ated with reduced inflammatory cytokine production in
the synovium. It remains to be established whether the
data in the preclinical models can be translated to the
clinical setting.
Discussion
Our main finding is that estrogen-mediated suppression
of inflammation as seen in the TT-DTH response and in
experimental arthritis is mediated via ERα but not ERβ.
The mechanisms underlying estrogen modulation of
inflammation are not well understood. Both pro-inflam-
matory and anti-inflammatory effects have been reported
(recently reviewed by Straub [20]. The dualistic action of
estrogens is, among others, explained by the concentra-
Table 2: Suppression of the tetanus-specific DTH response is ERα-mediated
mm
swelling
Uterus weight
(mg)
Vehicle po 1.2 ± 0.4 19.9 ± 7.0
Dexamethasone
3 mg/kg po 0.0 ± 0.0* 29.7 ± 17.4
EE 0.025 mg/kg po 0.7 ± 0.4 109.5 ± 23.8*
EE 0.25 mg/kg po 0.4 ± 0.2* 91.1 ± 14.4*
EE 2.5 mg/kg po 0.6 ± 0.3* 84.8 ± 17.1*
Vehicle po 1.1 ± 0.4 11.1 ± 1.6
Dexamethasone
3 mg/kg po 0.0 ± 0.0* 14.7 ± 3.5
ERA-63 1.5 mg/kg po 0.7 ± 0.3* 136.6 ± 19.9*
ERA-63 3 mg/kg po 0.5 ± 0.2* 113.6 ± 15.4*
ERA-63 6 mg/kg po 0.4 ± 0.2* 92.1 ± 14.5*
Vehicle sc 1.3 ± 0.1 13.4 ± 0.8
EE 0.25 mg/kg sc 0.5 ± 0.1* 148.8 ± 6.4*
ERB-79 3 mg/kg sc 1.1 ± 0.2 14.8 ± 1.8
Mice (n = 8 per group) were ovariectomized at day -14. Animals were treated daily for 10 days (day -1 to day 9) with ethinyl estradiol (EE) 
(0.025, 0.25 and 2.5 mg/kg), ERA-63 (1.5, 3 and 6 mg/kg), the positive control dexamethasone (3 mg/kg) or vehicle (0.5% gelatin and 5% 
mannitol in water). ERB-79 was dosed subcutaneously at 3 mg/kg per day (2 × 1.5 mg/kg). Animals were immunized at day 0 and boosted at 
day 7. Twenty four hours after challenge the footpad swelling was measured. Forty eight hours after challenge mice were euthanized and the 
uterus was dissected and weighed. Statistical analysis was performed with analysis of variance. * P < 0.05. DTH, delayed type hypersensitivity; 
ER, estrogen receptor; po, orally; sc, subcutaneous.Dulos et al. Arthritis Research & Therapy 2010, 12:R101
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tion of circulating estrogen, the differential expression of
ERα or ERβ in different cell types and the microenviron-
ment involved impacting the class of the immune
response. Here, we focused on defining the contribution
of ERα or ERβ to modulation of the inflammatory
response in experimental rat and mouse models.
Previously, ERβ-mediated suppression of inflammation
in Lewis rat AA was reported [25]. This prompted us to
study the effects of EE and our selective ERB-79 in rat
AA. Interestingly, our data showed significant suppres-
sion of signs and symptoms in rat AA with EE but not
with ERB-79, suggesting that in this model the suppres-
sion of arthritis is ERα-mediated. Thus, our findings do
not confirm the reported effects of an other ERβ agonistic
compound (ERB-041) in rat AA [25]. This discrepancy
may be explained by a higher potency and selectivity of
ERB-79 (484-fold over ERα). The combined data on ERB-
79 selectivity, PharmacoKinetics (PK) and the results of
the ERα titration study in vivo provides evidence that
ERB-79 at 3 mg/kg subcutaneous does not demonstrate
significant ERα-mediated activity in vivo, but is very
likely to engage ERβ.
Next, we chose to further study the role of the different
ERs in mice in vivo using well-described ERα and ERβ
knockout mice (compared with wild type) and two highly
selective compounds from our compound libraries,
which agonistically engage ERα (ERA-63) or ERβ (ERB-
79) for cross comparison. This approach was inspired by
the notions that: female mice, as seen in the human situa-
tion, show pregnancy-associated protection of joint dis-
ease with post-partum flares of arthritis [4,5]; and effects
of estrogens are best studied in vivo representing a system
with near physiological levels of ERα and ERβ allowing
for ER cross regulation and signaling in context.
Suppressive estrogen effects on DTH responses have
been observed previously [37,38]. Also, blocking of ERs
by the antagonist ICI 182,780 significantly increased the
DTH response [38]. In addition, Islander and colleagues
[37] showed that E2 decreased the DTH response in wild
t y p e  m i c e  w h e r e a s  t h i s  w a s  n o t  s e e n  i n  E R α β  d o u b l e
knockout mice. These data substantiate the role of estro-
gens in suppression of the DTH response but do not elu-
cidate the relative roles of ERα or ERβ in this process.
Our study is the first to show that treatment with a selec-
tive ERα agonist (ERA-63), but not with an ERβ agonist
(ERB-79), significantly reduces antigen-specific swelling
in the TT-DTH model. This was further confirmed by the
use of ERα- and Erβ knockout mice where the ERα ago-
nist ERA-63 decreased the DTH response in both wild
type and ERβ-/- but not in ERα-/- mice.
Previous studies have demonstrated effective treatment
of inflammation in models of autoimmune disease using
estrogens [8-10,25]. Also, estrogens were effective in sup-
pression of joint inflammation and clinical signs of arthri-
tis in mouse and rat CIA [23,24,39,40]. Moreover, ER-
receptor blockade using the ER antagonist ICI 182,780
triggered an earlier onset and increased severity of CIA
[10]. A number of studies using different selective ER
Figure 2 ERA-63 inhibits the tetanus-specific delayed type hyper-
sensitivity response in WT and ERβKO but not in the ERαKO mice. 
Mice were ovariectomized at day -14. Mice (n = 8 per group) were oral-
ly treated daily with ERA-63 at 6 mg/kg or vehicle gelatin-mannitol 
from day -1 to day 9. At day 0, animals were immunized with tetanus 
toxoid (TT) in dimethyl dioctadecyl ammonium bromide. At day 7, an-
imals were challenged with TT in Al(OH)3. The left control footpad re-
ceived vehicle only. (A) At autopsy (forty eight hours later) the uterus 
was removed and weighed. (B) Twenty-four hours later the left and 
right hind footpad thickness was measured and the delta mm of anti-
gen-specific footpad swelling was calculated according to the follow-
ing formula: [(swelling left (mm) minus swelling right (mm)]. Data are 
representative for three independent experiments. Statistical analysis 
was performed with the analysis of variance test. ** P ≤ 0.01, *** P ≤ 
0.001. ER, estrogen receptor; WT, wild type.
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modulators in experimental models of autoimmunity
suggest that suppression of inflammation is ERα-medi-
ated rather than ERβ-mediated [41]. Recently, the study
by Yh and colleagues showed that estrogen-mediated
modulation of inflammatory symptoms in mouse anti-
gen-induced arthritis was ERα-mediated. An ERβ selec-
tive compound (8beta-VE2) had no effect in this model
[42]. In addition, it has been suggested that ERα, in con-
trast to ERβ, has a major role in bone homeostasis and
therefore may protect against inflammation-induced
bone loss [43].
To confirm that estrogen-mediated suppression of
inflammation is ERα-mediated in ongoing arthritis, mice
with CIA, having scores ranging between 0.25 and 1.25,
were treated with EE and ERA-63. ERA-63 strongly sup-
pressed the ongoing arthritic process as evidenced by
both a significant reduction of the AUC and a reduction
in joint histopathology scores. Moreover, we observed
significantly decreased serum COMP levels in the ERA-
63 and EE-treated mice. The reductions in COMP levels
were associated with prevention of cartilage destruction
as evidenced by histopathological examination.
Figure 3 Suppression of arthritis in collagen-induced arthritis is ERα mediated. DBA/1J mice were immunized at day 0 and boosted at day 21. 
Arthritic animals (n = 12 per group) were daily, orally (p.o.) treated with vehicle (gelatin-mannitol), prednisolone (1.5 mg/kg or 3 mg/kg), (a) ethinyl 
estradiol (EE) at (0.025, 0.25 and 2.5 mg/kg) or the (c) estrogen receptor (ER)α agonist ERA-63 (0.75, 1.5 and 3 mg/kg). (a and c) The severity of arthritis 
was assessed by visual examination of a total of four paws/mouse (maximum is eight per mouse). The area under the curve (AUC) of the overall arthritis 
score is computed as a measure for the arthritis severity per animal during the 19 to 21 days of drug treatment for (b) EE and (d) ERA-63, respectively.
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Experimental and clinical studies have established
prominent roles for TNFα, IL-6 and IL-1 inflammatory
pathways in arthritis. In CIA, an increase in the arthritis
score of the knee joints was associated with an increase in
IL-1 mRNA levels [33]. In addition, suppression of CIA
was observed using antibodies against TNFα and IL-1
[32]. We showed that reduction in symptoms and associ-
ated joint pathology by ERA-63 was associated with sig-
nificantly reduced IL-1β, IL-6, IL-12p40, KC and
RANTES protein levels in the synovium. This is in line
with previous studies showing estrogen-mediated sup-
pression of nuclear factor (NF) κB activation. It is tempt-
Figure 4 ERα-mediated suppression of joint destruction. Arthritic DBA/1J mice (n = 12 per group) were orally (p.o.) treated daily with vehicle (gel-
atin-mannitol), prednisolone (1.5 or 3 mg/kg), (a) ethinyl estradiol (EE) at (0.025, 0.25 and 2.5 mg/kg) or the (b) estrogen receptor (ER)α agonist ERA-
63 (0.75, 1.5 and 3 mg/kg). At autopsy, knees were evaluated using histopathology (infiltration and cartilage destruction), hind paws were evaluated 
using X-ray analysis (bone destruction) and serum was used for COMP analysis (cartilage destruction) (a, EE) and (b, ERA-63). Statistical analyses for 
COMP and for the area under the curve arthritis score, one-way analysis of variance was used with n = 12 per experimental group (* P ≤ 0.05).
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ing to speculate that ER cross talk with NFκB may be
ligand dependent. Selective ER modulators or ERα-selec-
tive ligands may thus have differential effects in different
cells. Indeed, E2 was found to suppress NFκB activation
whereas the selective ER modulators raloxifene or tamox-
ifene were inactive in this model system [41].
The role of estrogens in inflammation was recently
reviewed [20]. It was proposed, substantiated by numer-
ous studies, that the humoral immune response is stimu-
lated at a broad range of physiologic estrogen
concentrations (post-menopausal through to late preg-
nancy levels) whereas both the innate and the cellular
response are suppressed at high physiologic estrogen
concentrations (pregnancy levels). This hypothesis
would, to a certain extent, explain the higher frequencies
of certain autoimmune diseases with a strong B cell com-
ponent (for example, SLE) in women in the reproductive
years. Moreover, it would explain the increase in develop-
ment of autoimmunity (for example, RA) in menopause
when estrogen levels are relatively low.
Our studies unequivocally show that in DTH and in
two experimental arthritis models, ERα agonism is
needed to suppress the inflammatory response. There is
still some controversy around the topic of additional ERs
such as GPR30 [44]. Our current study and the study by
Engdahl and colleagues confirm the important role of
ERα in arthritis suppression and imply that a role for
GPR30 in inflammation is not likely [45]. Further studies
will be needed to elucidate the relative roles of ERα and
ERβ in human autoimmune diseases.
Differential effects of ERα and ERβ ligands in EAE have
been described [46,47]. Moreover, clinical trials with
oestrogens in multiple sclerosis have been described
showing immune modulatory effects [48,49]. Clinical tri-
als involving estrogen suppletion in RA have led to con-
flicting reports. Early studies, without placebo-controlled
treatment groups, demonstrated efficacy of estrogen
treatment in RA [50,51]. In placebo-controlled trials,
however, different outcomes were documented. Studies
with clinical efficacy [52,53] but also studies with mar-
ginal [54] or no improvement have been reported [55].
The reasons for the contradictory results on clinical signs
in these studies were attributed to selection of the
patients, design of the study and the readouts, the power
to detect a clinical effect and the use of a combination of
estrogens and progestagens, which may obscure effects of
estrogen alone [5,56]. Importantly, in several trials,
changes in bone formation (osteocalcin) and bone
resorption (CTXII) markers were in agreement with
favorable effects of estrogens on bone mineral density
[54]. Recently, the data from a first proof of concept trial
in postmenopausal female RA patients (on concomitant
Table 3: ERα-mediated suppression of arthritis is associated with decreased cytokine and chemokine levels
IL-1β
(pg/mg protein)
IL-6
(pg/mg protein)
IL-12p40
(pg/mg protein)
KC
(pg/mg protein)
RANTES
(pg/mg protein)
Vehicle: 91 ± 22 6 ± 3 5 ± 2 17 ± 5 3.2 ± 1.2
EE 0.025 mg/kg 
po:
13 ± 38* 12 ± 11 1.9 ± 0.5* 5 ± 2 0.9 ± 0.2*
EE 0.25 mg/kg po: 23 ± 18* 1.0 ± 0.4* 1.5 ± 0.1* 5 ± 4 0.8 ± 0.4*
EE 2.5 mg/kg po 4 ± 2* 0.3 ± 0.3* 0.1 ± 0.1* 2 ± 0.3 0.2 ± 0.1*
Vehicle: 110.4 10.7 3.7 19.1 3.3
Prednisolone 3 
mg/kg po
0.6 1.3 0.1 0.6 0
ERA-63 0.75 mg/
kg po
71.4 21.3 2.2 20.5 1.4
ERA-63 1.5 mg/kg 
po
5.9 0.7 0.8 1.3 0.2
ERA-63 3 mg/kg 
po
2.9 2.0 0.6 2.3 0.2
Biopsies of four mice (n = 4 per cage) were pooled and processed for cytokine and chemokine detection, thereby yielding three samples per 
treatment group for Luminex measurement. Results are presented as mean picograms per mg total protein obtained from three 
measurements per treatment group in the first experiment comparing vehicle with ethinyl estradiol (EE; 0.025, 0.25 and 2.5 mg/kg). The 
standard error of the mean are given. Statistical analysis was performed with the two-tailed Mann-Whitney test. Statistically significant 
differences (P ≤ 0.05) when compared with the vehicle treatment group is indicated with an asterisk (*). Next, results are based on one 
measurement on pooled synovial lysates obtained from 12 animals in total (n = 12 mice; 1 biopsy per mouse) in the second experiment 
comparing vehicle with ERA-63 (0.75, 1.5 and 3 mg/kg). Levels are expressed as picograms per mg total protein. ER, estrogen receptor; po, 
orally. Chemokine (C-C motif) ligand 5 also known as CCL5 or RANTES and the murine IL-8 homoloque KC.Dulos et al. Arthritis Research & Therapy 2010, 12:R101
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treatment with methotrexate or sulfasalazine) failed to
demonstrate efficacy of ERA-63 in spite of good pharma-
codynamics [57]. It is feasible that the length of the treat-
ment period (10 weeks) is too short to modulate clinical
disease expression under the cover of concurrent treat-
ment. Alternatively, ERα agonism is not beneficial in this
group of RA patients. Clearly, further studies are needed
to elucidate the relative roles of ERα and ERβ in human
autoimmune disease in order to effectively translate this
knowledge to novel targeted therapies.
Conclusions
ERα, but not ERβ, is key in ER-mediated suppression of
experimental arthritis. It remains to be investigated how
these findings translate to human autoimmune disease.
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